An expeditious synthesis of 3-(difluoromethoxy)- and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines
摘要:
An expeditious and concise synthesis of 3-(difluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines is described. Starting from N-benzyl piperidone, the key intermediates leading to these two biologically desirable synthones were rapidly assembled by inverse electron demand Diels-Alder (IEDA) reaction utilizing microwave irradiation. The scope of the microwave methodology developed herein was extended to other ketones. (c) 2008 Elsevier Ltd. All rights reserved.
Imidazole and imidazoline derivatives and uses thereof
申请人:Synaptic Pharmaceutical Corporation
公开号:US20020019390A1
公开(公告)日:2002-02-14
This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;
2
adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;
2
receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
Pyrazole Compounds Useful In The Treatment Of Inflammation
申请人:Nilsson Peter
公开号:US20070225318A1
公开(公告)日:2007-09-27
There is provided compounds of formula (I), wherein R
1
, R
2
, R
a
and R
b
have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.
This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.